HUTCHMED (China) Limited(HCM)Earnings, Financials & Key Ratios
HCM•NASDAQ
$13.43
$2.31B mkt cap·61.0× P/E·Price updated May 6, 2026
AboutHUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.Show more
- Revenue$630M-24.8%
- EBITDA-$31M-218.0%
- Net Income$38M-62.6%
- EPS (Diluted)0.22-63.3%
- Gross Margin44.64%-17.5%
- EBITDA Margin-4.98%-256.9%
- Operating Margin-6.94%-416.3%
- Net Margin5.99%-50.2%
- ROE4.98%-65.9%
- ROIC-5.23%-270.1%
- Debt/Equity0.12+0.4%
- Interest Coverage-15.22-162.9%
HCM Key Insights
HUTCHMED (China) Limited (HCM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 25.2%
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
HCM Price & Volume
HUTCHMED (China) Limited (HCM) stock price & volume — 10-year historical chart
Loading chart...
HCM Growth Metrics
HUTCHMED (China) Limited (HCM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years21.24%
5 Years25.2%
3 Years20.96%
TTM-1.41%
Profit CAGR
10 Years21.52%
5 Years-
3 Years-
TTM1212.42%
EPS CAGR
10 Years15.74%
5 Years-
3 Years-
TTM1151.59%
Return on Capital
10 Years-23.59%
5 Years-27.07%
3 Years-16.58%
Last Year-4.93%
HCM Recent Earnings
HUTCHMED (China) Limited (HCM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (67%)●Beat Revenue 1/12 qtrs (17%)
Q2 2026Latest
Mar 5, 2026EPS
—
Est $2.50
Revenue
$271M
Est $291M
-6.7%
Q3 2025
Aug 7, 2025EPS
$1.30
Est $1.46
-11.0%
Revenue
$139M
Est $330M
-58.0%
Q3 2025
Jul 2, 2025EPS
$1.30
Revenue
$139M
Q2 2025
Mar 19, 2025EPS
$0.03
Est $0.09
+137.9%
Revenue
$162M
Est $319M
-49.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 5, 2026 | —vs $2.50 | $271Mvs $291M-6.7% |
| Q3 2025 | Aug 7, 2025 | $1.30vs $1.46-11.0% | $139Mvs $330M-58.0% |
| Q3 2025 | Jul 2, 2025 | $1.30 | $139M |
| Q2 2025 | Mar 19, 2025 | $0.03vs $0.09+137.9% | $162Mvs $319M-49.2% |
Based on last 12 quarters of dataView full earnings history →
HCM Peer Comparison
HUTCHMED (China) Limited (HCM) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ZLAB | 2.32B | 21.01 | -13.13 | 15.33% | -38.15% | -22.81% | 0.31 | |
 LEGN | 5.35B | 28.96 | -8.99 | 64.47% | -28.83% | -29.22% | 0.41 | |
 CAN | 355.58M | 0.55 | -1.23 | 96.69% | -39.68% | -48.08% | 0.13 | |
 ABBV | 362.56B | 204.98 | 86.49 | 8.57% | 6.91% | 62.15% | ||
 MRK | 280.48B | 113.56 | 15.60 | 1.18% | 28.12% | 36.14% | 0.96 | |
 BMY | 115.43B | 56.54 | 16.39 | -0.22% | 15.01% | 38.96% | 2.55 | |
 EXEL | 12.37B | 48.70 | 17.52 | 6.98% | 35.08% | 40.21% | 0.08 | |
 INCY | 19.95B | 99.85 | 15.58 | 21.22% | 26.71% | 29.31% | 0.01 |
Compare HCM vs Peers
HUTCHMED (China) Limited (HCM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
HCM Income Statement
HUTCHMED (China) Limited (HCM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 216.08M | 241.2M | 214.11M | 204.89M | 227.98M | 356.13M | 426.41M | 838M | 630.2M | 602.2M |
| Revenue Growth % | 21.25% | 11.63% | -11.23% | -4.31% | 11.27% | 56.21% | 19.73% | 96.52% | -24.8% | -1.41% |
| Cost of Goods Sold | 156.33M | 175.82M | 143.94M | 160.15M | 188.52M | 258.23M | 311.1M | 384.45M | 348.88M | 548.43M |
| COGS % of Revenue | 72.35% | 72.89% | 67.23% | 78.16% | 82.69% | 72.51% | 72.96% | 45.88% | 55.36% | - |
| Gross Profit | 59.75M▲ 0% | 65.38M▲ 9.4% | 70.17M▲ 7.3% | 44.74M▼ 36.2% | 39.46M▼ 11.8% | 97.89M▲ 148.1% | 115.31M▲ 17.8% | 453.55M▲ 293.3% | 281.32M▼ 38.0% | 53.76M▲ 0% |
| Gross Margin % | 27.65% | 27.11% | 32.77% | 21.84% | 17.31% | 27.49% | 27.04% | 54.12% | 44.64% | 8.93% |
| Gross Profit Growth % | -11.38% | 9.42% | 7.31% | -36.24% | -11.8% | 148.1% | 17.79% | 293.35% | -37.97% | - |
| Operating Expenses | 106.59M | 118.8M | 161.01M | 189.76M | 236.13M | 426.21M | 523M | 436.23M | 321.93M | 73.46M |
| OpEx % of Revenue | 49.33% | 49.25% | 75.2% | 92.61% | 103.57% | 119.68% | 122.65% | 52.06% | 51.08% | - |
| Selling, General & Admin | 39.58M | 43.28M | 48.65M | 52.93M | 61.35M | 127.13M | 136.11M | 133.18M | 112.91M | 96.73M |
| SG&A % of Revenue | 18.32% | 17.94% | 22.72% | 25.84% | 26.91% | 35.7% | 31.92% | 15.89% | 17.92% | - |
| Research & Development | 66.87M | 50.67M | 78.82M | 91.94M | 111.23M | 207.45M | 267.59M | 303.06M | 213.37M | 190.1M |
| R&D % of Revenue | 30.95% | 21.01% | 36.81% | 44.87% | 48.79% | 58.25% | 62.75% | 36.16% | 33.86% | - |
| Other Operating Expenses | 609K | 116K | -781K | 44.88M | 63.54M | 91.64M | 119.31M | 0 | -4.35M | -2M |
| Operating Income | -46.7M▲ 0% | -53.42M▼ 14.4% | -92.64M▼ 73.4% | -145.02M▼ 56.5% | -198.62M▼ 37.0% | -344.29M▼ 73.3% | -409.77M▼ 19.0% | 18.38M▲ 104.5% | -43.7M▼ 337.9% | -19.7M▲ 0% |
| Operating Margin % | -21.61% | -22.15% | -43.27% | -70.78% | -87.12% | -96.68% | -96.1% | 2.19% | -6.94% | -3.27% |
| Operating Income Growth % | -377.91% | -14.39% | -73.43% | -56.54% | -36.96% | -73.34% | -19.02% | 104.48% | -337.85% | - |
| EBITDA | -44.39M | -50.84M | -89.05M | -140.08M | -192.56M | -337.1M | -401.11M | 26.58M | -31.36M | -7.49M |
| EBITDA Margin % | -20.54% | -21.08% | -41.59% | -68.37% | -84.46% | -94.66% | -94.07% | 3.17% | -4.98% | -1.24% |
| EBITDA Growth % | -472.36% | -14.52% | -75.16% | -57.3% | -37.46% | -75.07% | -18.99% | 106.63% | -217.99% | 93.2% |
| D&A (Non-Cash Add-back) | 2.3M | 2.58M | 3.59M | 4.94M | 6.06M | 7.19M | 8.66M | 8.21M | 12.34M | 12.21M |
| EBIT | -45.7M | -52.08M | -85.65M | -140.07M | -188.95M | -215.15M | -409.77M | 59.07M | 1.76M | -19.7M |
| Net Interest Income | -1.13M | -235K | 4.97M | 3.91M | 2.45M | 1.48M | 8.95M | 35.39M | 37.21M | 37.21M |
| Interest Income | 502K | 1.22M | 5.98M | 4.94M | 3.24M | 2.08M | 9.6M | 36.15M | 40.08M | 37.21M |
| Interest Expense | 1.63M | 1.46M | 1.01M | 1.03M | 787K | 592K | 652K | 759K | 2.87M | 0 |
| Other Income/Expense | -659K | -119K | 5.99M | 5.28M | 87.74M | 188.96M | 51.52M | 87.23M | 89.07M | 554.73M |
| Pretax Income | -47.36M▲ 0% | -53.54M▼ 13.1% | -86.66M▼ 61.9% | -141.1M▼ 62.8% | -110.88M▲ 21.4% | -155.33M▼ 40.1% | -360.24M▼ 131.9% | 105.6M▲ 129.3% | 45.36M▼ 57.0% | 535.03M▲ 0% |
| Pretax Margin % | -21.92% | -22.2% | -40.47% | -68.87% | -48.64% | -43.62% | -84.48% | 12.6% | 7.2% | 88.85% |
| Income Tax | 4.33M | 3.08M | 3.96M | 3.27M | 4.83M | 11.92M | -283K | 4.51M | 7.19M | 67.47M |
| Effective Tax Rate % | -9.15% | -5.75% | -4.57% | -2.32% | -4.36% | -7.67% | 0.08% | 4.27% | 15.85% | 12.61% |
| Net Income | 11.7M▲ 0% | -26.74M▼ 328.6% | -74.81M▼ 179.8% | -103.68M▼ 38.6% | -125.73M▼ 21.3% | -194.65M▼ 54.8% | -360.83M▼ 85.4% | 100.78M▲ 127.9% | 37.73M▼ 62.6% | 466.88M▲ 0% |
| Net Margin % | 5.41% | -11.08% | -34.94% | -50.6% | -55.15% | -54.66% | -84.62% | 12.03% | 5.99% | 77.53% |
| Net Income Growth % | 46.35% | -328.56% | -179.78% | -38.6% | -21.27% | -54.81% | -85.38% | 127.93% | -62.56% | 1212.42% |
| Net Income (Continuing) | -51.66M | -22.96M | -71.29M | -103.68M | -115.52M | -167.04M | -360.39M | 101.09M | 38.17M | 467.56M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 19.79M | 23.23M | 23.26M | 24.89M | 34.83M | 52.62M | 26.5M | 12.85M | 11.92M | 12.86M |
| EPS (Diluted) | 0.10▲ 0% | -0.22▼ 320.0% | -0.55▼ 150.0% | -1.10▼ 100.0% | -0.90▲ 18.2% | -1.25▼ 38.9% | -2.15▼ 72.0% | 0.60▲ 127.9% | 0.22▼ 63.3% | 2.68▲ 0% |
| EPS Growth % | 131.25% | -320% | -150% | -100% | 18.18% | -38.89% | -72% | 127.91% | -63.33% | 1151.59% |
| EPS (Basic) | 0.10 | -0.22 | -0.55 | -1.10 | -0.90 | -1.25 | -2.15 | 0.60 | 0.22 | - |
| Diluted Shares Outstanding | 119.94M | 123.43M | 132.85M | 133.14M | 139.59M | 158.54M | 169.43M | 173.84M | 174.57M | 174.51M |
| Basic Shares Outstanding | 119.43M | 123.43M | 132.85M | 133.14M | 139.59M | 158.54M | 169.43M | 169.93M | 171.07M | 174.98M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
HCM Balance Sheet
HUTCHMED (China) Limited (HCM) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 167.38M | 432.19M | 370.54M | 317.02M | 530.74M | 1.21B | 839.89M | 1.1B | 1.07B | 1.59B |
| Cash & Short-Term Investments | 103.7M | 358.3M | 300.95M | 217.17M | 435.18M | 1.01B | 631M | 886.34M | 836.11M | 1.36B |
| Cash Only | 79.43M | 85.27M | 86.04M | 121.16M | 235.63M | 377.54M | 313.28M | 283.59M | 153.96M | 1.36B |
| Short-Term Investments | 24.27M | 273.03M | 214.91M | 96.01M | 199.55M | 634.16M | 317.72M | 602.75M | 682.15M | 0 |
| Accounts Receivable | 48.93M | 62.11M | 43.85M | 77.17M | 47.87M | 147.73M | 126.72M | 150.46M | 167.74M | 146.97M |
| Days Sales Outstanding | 82.65 | 93.99 | 74.75 | 137.48 | 76.64 | 151.41 | 108.47 | 65.53 | 97.15 | 93.53 |
| Inventory | 12.82M | 11.79M | 12.31M | 16.21M | 19.77M | 35.76M | 56.69M | 50.26M | 50.4M | 0 |
| Days Inventory Outstanding | 29.94 | 24.47 | 31.21 | 36.94 | 38.27 | 50.54 | 66.51 | 47.72 | 52.73 | 24.83 |
| Other Current Assets | 610K | 19.84M | 8.33M | 2.71M | 20.89M | 2.76M | 3.15M | 2.68M | 3.3M | 80.84M |
| Total Non-Current Assets | 175.06M | 165.74M | 161.58M | 148.1M | 193.38M | 160.59M | 189.56M | 182.93M | 207.64M | 183.61M |
| Property, Plant & Equipment | 11.17M | 15.48M | 17.79M | 27.48M | 45.31M | 66.32M | 84.67M | 104.39M | 97M | 94.57M |
| Fixed Asset Turnover | 19.34x | 15.58x | 12.04x | 7.46x | 5.03x | 5.37x | 5.04x | 8.03x | 6.50x | 6.29x |
| Goodwill | 3.14M | 3.31M | 3.19M | 3.11M | 3.31M | 3.38M | 3.14M | 3.06M | 2.99M | 0 |
| Intangible Assets | 469K | 430K | 347K | 275K | 227K | 163K | 3.22M | 21K | 0 | 0 |
| Long-Term Investments | 158.51M | 144.24M | -76.6M | 2.93M | -60.04M | -557.68M | -243.94M | 48.41M | -599.39M | -499.33M |
| Other Non-Current Assets | 1.77M | 1.65M | 216.27M | 113.48M | 203.06M | 639M | 327.1M | 11.59M | 707.04M | 895.71M |
| Total Assets | 342.44M▲ 0% | 597.93M▲ 74.6% | 532.12M▼ 11.0% | 465.12M▼ 12.6% | 724.12M▲ 55.7% | 1.37B▲ 89.6% | 1.03B▼ 25.0% | 1.28B▲ 24.3% | 1.27B▼ 0.4% | 1.78B▲ 0% |
| Asset Turnover | 0.63x | 0.40x | 0.40x | 0.44x | 0.31x | 0.26x | 0.41x | 0.65x | 0.49x | 0.39x |
| Asset Growth % | 49.05% | 74.61% | -11.01% | -12.59% | 55.68% | 89.56% | -25% | 24.32% | -0.44% | 80.83% |
| Total Current Liabilities | 95.12M | 104.6M | 85.48M | 113.1M | 158.4M | 311.66M | 353.9M | 403.03M | 376.56M | 342.41M |
| Accounts Payable | 35.54M | 24.36M | 25.63M | 23.96M | 31.61M | 41.18M | 71.11M | 36.33M | 42.52M | 43.73M |
| Days Payables Outstanding | 82.98 | 50.58 | 64.98 | 54.61 | 61.21 | 58.2 | 83.44 | 34.49 | 44.49 | 28.7 |
| Short-Term Debt | 19.96M | 29.99M | 432K | 366K | 3.19M | 26.91M | 0 | 31.16M | 23.37M | 25.6M |
| Deferred Revenue (Current) | 1.86M | 2.58M | 2.54M | 2.11M | 1.6M | 15.55M | 13.35M | 57.64M | 0 | 0 |
| Other Current Liabilities | 9.31M | 37.4M | 48.17M | 8.09M | -76K | 40.95M | 41.1M | 228.93M | 290.08M | 47.93M |
| Current Ratio | 1.76x | 4.13x | 4.33x | 2.80x | 3.35x | 3.89x | 2.37x | 2.72x | 2.83x | 2.83x |
| Quick Ratio | 1.62x | 4.02x | 4.19x | 2.66x | 3.23x | 3.77x | 2.21x | 2.60x | 2.70x | 2.70x |
| Cash Conversion Cycle | 29.61 | 67.88 | 40.98 | 119.81 | 53.71 | 143.75 | 91.55 | 78.76 | 105.4 | 89.66 |
| Total Non-Current Liabilities | 43.26M | 8.37M | 34.38M | 39.12M | 46.77M | 21.49M | 38.67M | 133.36M | 125.78M | 191.6M |
| Long-Term Debt | 26.83M | 579K | 26.74M | 26.82M | 26.86M | 0 | 18.1M | 48.19M | 59.43M | 93.44M |
| Capital Lease Obligations | 0 | 0 | 579K | 3.05M | 6.06M | 7.16M | 5.2M | 2.86M | 4.09M | 14.56M |
| Deferred Tax Liabilities | 4M | 4.45M | 4.84M | 3.16M | 5.06M | 2.77M | 2.71M | 1.48M | 2.99M | 2.99M |
| Other Non-Current Liabilities | 13.03M | 538K | 859K | 5.96M | 8.3M | 14.33M | 12.47M | 11.35M | 10.84M | 291.89M |
| Total Liabilities | 138.38M | 112.97M | 119.86M | 152.22M | 205.17M | 333.15M | 392.57M | 536.39M | 502.34M | 534.02M |
| Total Debt | 46.79M | 29.99M | 26.74M | 33.45M | 38.9M | 38.98M | 27.01M | 86.13M | 89.82M | 93.44M |
| Net Debt | -32.64M | -55.28M | -59.3M | -87.71M | -196.73M | -338.56M | -289.98M | -197.46M | -64.14M | -1.27B |
| Debt / Equity | 0.23x | 0.06x | 0.06x | 0.11x | 0.07x | 0.04x | 0.04x | 0.12x | 0.12x | 0.12x |
| Debt / EBITDA | - | - | - | - | - | - | - | 3.24x | - | -12.48x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | -7.43x | - | 169.70x |
| Interest Coverage | -28.63x | -36.71x | -91.81x | -140.80x | -252.37x | -581.57x | -628.48x | 24.21x | -15.22x | - |
| Total Equity | 204.06M▲ 0% | 484.97M▲ 137.7% | 412.25M▼ 15.0% | 312.9M▼ 24.1% | 518.95M▲ 65.8% | 1.04B▲ 100.3% | 636.87M▼ 38.7% | 743.39M▲ 16.7% | 771.85M▲ 3.8% | 1.24B▲ 0% |
| Equity Growth % | 99.52% | 137.66% | -14.99% | -24.1% | 65.85% | 100.31% | -38.73% | 16.73% | 3.83% | 137.95% |
| Book Value per Share | 1.70 | 3.93 | 3.10 | 2.35 | 3.72 | 6.56 | 3.76 | 4.28 | 4.42 | 7.12 |
| Total Shareholders' Equity | 184.27M | 461.73M | 389M | 288.01M | 484.12M | 986.89M | 610.37M | 730.54M | 759.93M | 1.23B |
| Common Stock | 60.71M | 66.45M | 66.66M | 66.69M | 72.77M | 86.45M | 86.48M | 87.13M | 87.16M | 87.21M |
| Retained Earnings | -80.36M | -107.1M | -183M | -289.73M | -415.59M | -610.33M | -971.48M | -870.87M | -833.17M | -380.32M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -4.28M | 5.43M | -243K | -3.85M | 4.48M | 5.57M | -1.9M | -8.16M | -11.59M | -5.49M |
| Minority Interest | 19.79M | 23.23M | 23.26M | 24.89M | 34.83M | 52.62M | 26.5M | 12.85M | 11.92M | 12.86M |
HCM Cash Flow Statement
HUTCHMED (China) Limited (HCM) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -9.57M | -8.94M | -32.85M | -80.91M | -62.07M | -204.22M | -268.6M | 219.26M | 497K | 497K |
| Operating CF Margin % | -4.43% | -3.71% | -15.34% | -39.49% | -27.22% | -57.35% | -62.99% | 26.16% | 0.08% | - |
| Operating CF Growth % | -1.96% | 6.54% | -267.29% | -146.33% | 23.29% | -229.04% | -31.52% | 181.63% | -99.77% | 1162.87% |
| Net Income | 14.56M | -22.96M | -71.29M | -103.68M | -115.52M | -167.04M | -360.39M | 100.78M | 37.73M | 466.88M |
| Depreciation & Amortization | 2.34M | 2.58M | 3.59M | 4.94M | 6.06M | 7.19M | 8.66M | 8.21M | 12.34M | 12.21M |
| Stock-Based Compensation | 3.44M | 4.74M | 10.13M | 11.59M | 19.64M | 41.99M | 30.59M | 36.6M | 21.61M | 17.99M |
| Deferred Taxes | -33.22M | 20.82M | 17.68M | -10.27M | 552K | -115.14M | 0 | -102.76M | 0 | 0 |
| Other Non-Cash Items | 92K | 147K | 76K | 394K | -2.08M | -3.68M | -6.17M | 105.28M | -9.01M | -497.11M |
| Working Capital Changes | 3.22M | -14.26M | 6.96M | 16.11M | 29.27M | 32.46M | 58.7M | 71.15M | -62.17M | -32.53M |
| Change in Receivables | -7.26M | 2.74M | -459K | -553K | -4.69M | -35.63M | -14.45M | -21.34M | -41.57M | 9.93M |
| Change in Inventory | -3.43M | 1.05M | -557K | -4.21M | -3.62M | -16M | -21.21M | 4.13M | -772K | -2.31M |
| Change in Payables | 9.82M | -11.17M | 1.26M | -1.66M | 7.65M | 9.56M | 29.94M | -32.54M | 6.2M | 0 |
| Cash from Investing | -33.6M | -260.78M | 43.75M | 119.03M | -125.44M | -306.32M | 296.59M | -291.14M | -96.06M | -73.03M |
| Capital Expenditures | -4.33M | -5.02M | -6.36M | -8.56M | -19.58M | -16.76M | -36.66M | -32.61M | -17.93M | -17.09M |
| CapEx % of Revenue | 2% | 2.08% | 2.97% | 4.18% | 8.59% | 4.71% | 8.6% | 3.89% | 2.85% | - |
| Acquisitions | 0 | 0 | 0 | 8.69M | 0 | 159.12M | 324K | -2.99M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -29.27M | -255.76M | 50.12M | 0 | -2.33M | 930K | 16.49M | 0 | 1.28M | -55.94M |
| Cash from Financing | 92.44M | 273.2M | -8.23M | -1.49M | 296.43M | 650.03M | -82.76M | 48.66M | -30.67M | 11.22M |
| Debt Issued (Net) | -3.08M | -16.95M | -3.08M | -182K | 35.06K | -579.77K | -9.17M | 61.7M | 5.61M | 0 |
| Equity Issued (Net) | 1000K | 1000K | -1000K | -346K | 1000K | 1000K | -1000K | -1000K | -1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | -99.74M | -87.44M | 0 | 0 | 0 |
| Share Repurchases | -604K | -1.37M | -5.45M | -346K | -12.9M | -27.31M | -48.08M | -9.07M | -36.06M | 0 |
| Other Financing | -14.47M | -1.59M | -3.57M | -965K | -9.63M | 60.34M | 61.75M | -9.07M | -1M | 11.22M |
| Net Change in Cash | 47.49M▲ 0% | 5.83M▼ 87.7% | 771K▼ 86.8% | 35.12M▲ 4455.3% | 114.47M▲ 225.9% | 141.91M▲ 24.0% | -64.26M▼ 145.3% | -29.69M▲ 53.8% | -129.63M▼ 336.6% | -203.95M▲ 0% |
| Free Cash Flow | -13.9M▲ 0% | -13.96M▼ 0.5% | -39.21M▼ 180.8% | -89.48M▼ 128.2% | -81.65M▲ 8.8% | -220.98M▼ 170.7% | -305.26M▼ 38.1% | 186.65M▲ 161.1% | -17.44M▼ 109.3% | -49.66M▲ 0% |
| FCF Margin % | -6.43% | -5.79% | -18.31% | -43.67% | -35.81% | -62.05% | -71.59% | 22.27% | -2.77% | -8.25% |
| FCF Growth % | -9.34% | -0.47% | -180.84% | -128.19% | 8.75% | -170.66% | -38.14% | 161.14% | -109.34% | 24% |
| FCF per Share | -0.12 | -0.11 | -0.30 | -0.67 | -0.58 | -1.39 | -1.80 | 1.07 | -0.10 | -0.10 |
| FCF Conversion (FCF/Net Income) | -0.82x | 0.33x | 0.44x | 0.78x | 0.49x | 1.05x | 0.74x | 2.18x | 0.01x | -0.11x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.51M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HCM Key Ratios
HUTCHMED (China) Limited (HCM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 7.64% | -7.76% | -16.67% | -28.59% | -30.23% | -24.98% | -43.05% | 14.6% | 4.98% | 46.37% |
| Return on Invested Capital (ROIC) | -24.01% | -13.33% | -17.76% | -37.62% | -54.42% | -50.47% | -58.45% | 3.07% | -5.23% | -5.23% |
| Gross Margin | 27.65% | 27.11% | 32.77% | 21.84% | 17.31% | 27.49% | 27.04% | 54.12% | 44.64% | 8.93% |
| Net Margin | 5.41% | -11.08% | -34.94% | -50.6% | -55.15% | -54.66% | -84.62% | 12.03% | 5.99% | 77.53% |
| Debt / Equity | 0.23x | 0.06x | 0.06x | 0.11x | 0.07x | 0.04x | 0.04x | 0.12x | 0.12x | 0.12x |
| Interest Coverage | -28.63x | -36.71x | -91.81x | -140.80x | -252.37x | -581.57x | -628.48x | 24.21x | -15.22x | - |
| FCF Conversion | -0.82x | 0.33x | 0.44x | 0.78x | 0.49x | 1.05x | 0.74x | 2.18x | 0.01x | -0.11x |
| Revenue Growth | 21.25% | 11.63% | -11.23% | -4.31% | 11.27% | 56.21% | 19.73% | 96.52% | -24.8% | -1.41% |
HCM Frequently Asked Questions
HUTCHMED (China) Limited (HCM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
HUTCHMED (China) Limited (HCM) reported $602.2M in revenue for fiscal year 2024. This represents a 1491% increase from $37.9M in 2005.
HUTCHMED (China) Limited (HCM) saw revenue decline by 24.8% over the past year.
Yes, HUTCHMED (China) Limited (HCM) is profitable, generating $466.9M in net income for fiscal year 2024 (6.0% net margin).
Dividend & Returns
HUTCHMED (China) Limited (HCM) has a return on equity (ROE) of 5.0%. This is below average, suggesting room for improvement.
HUTCHMED (China) Limited (HCM) had negative free cash flow of $49.7M in fiscal year 2024, likely due to heavy capital investments.
Explore More HCM
HUTCHMED (China) Limited (HCM) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates